CMS stance on carotid stenting ignores science, kills innovation, SCAI doc argues

04/29/2013 | CardiovascularBusiness.com

Carotid stent therapy has been shown to be as effective as surgery in low-risk asymptomatic patients, yet CMS has upheld a 25-year-old noncoverage stance, without explanation, writes Dr. Christopher White, SCAI's immediate past president. Many observers believe CMS' position is the result of "turf battles," which have permitted the agency to disregard scientific results and to stifle medical innovation, Dr. White writes. The result, he says, is that patients are unable to opt for the treatment that may be best for them.

View Full Article in:

CardiovascularBusiness.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA